188 related articles for article (PubMed ID: 32682445)
21. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
22. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
23. KCNMA1-AS1 attenuates apoptosis of epithelial ovarian cancer cells and serves as a risk factor for poor prognosis of epithelial ovarian cancer.
Ma SY; Wei P; Qu F
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4629-4641. PubMed ID: 31210304
[TBL] [Abstract][Full Text] [Related]
24. Exploring the prognostic significance of preoperative high normocalcemia in epithelial ovarian carcinoma.
Cho HW; Ouh YT; Hong JH; Lee JK
Arch Gynecol Obstet; 2021 Mar; 303(3):803-810. PubMed ID: 33078229
[TBL] [Abstract][Full Text] [Related]
25. Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.
Zhang Y; Hua W; Niu LC; Li SM; Wang YM; Shang L; Zhang C; Li WN; Wang R; Chen BL; Xin XY; Zhang YQ; Wang J
Tumour Biol; 2016 Jul; 37(7):9423-31. PubMed ID: 26781874
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of Increased Expression of Annexin A10 (ANXA10) in Serous Epithelial Ovarian Cancer.
Wang J; Zhao S; Wang F; Wang J; Zhang Y
Med Sci Monit; 2019 Jul; 25():5666-5673. PubMed ID: 31363077
[TBL] [Abstract][Full Text] [Related]
28. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
29. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
30. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Sharma A; Malik PS; Khurana S; Kumar S; Bhatla N; Ray MD; Kumar L
Indian J Med Res; 2019 Dec; 150(6):575-583. PubMed ID: 32048620
[TBL] [Abstract][Full Text] [Related]
31. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
Farolfi A; Scarpi E; Greco F; Bergamini A; Longo L; Pignata S; Casanova C; Cormio G; Bologna A; Orditura M; Zavallone L; Attademo L; Gallà V; Franzese E; Pigozzi E; Loizzi V; Giorda G; Giardina D; Cioffi R; De Giorgi U
Sci Rep; 2020 Oct; 10(1):18190. PubMed ID: 33097745
[TBL] [Abstract][Full Text] [Related]
32. Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group.
Canzler U; Lück HJ; Neuser P; Sehouli J; Burges A; Harter P; Schmalfeldt B; Aminossadati B; Mahner S; Kommoss S; Wimberger P; Pfisterer J; de Gregorio N; Hasenburg A; Gropp-Meier M; El-Balat A; Jackisch C; du Bois A; Meier W; Wagner U
Arch Gynecol Obstet; 2020 May; 301(5):1267-1274. PubMed ID: 32277253
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
34. Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer.
Komura N; Mabuchi S; Yokoi E; Shimura K; Kawano M; Matsumoto Y; Kimura T
Int J Gynecol Cancer; 2019 Jul; 29(6):1057-1063. PubMed ID: 31203199
[TBL] [Abstract][Full Text] [Related]
35. The diagnostic, prediction of postoperative recurrence and prognostic value of HE4 in epithelial ovarian cancer.
Chen L; Yang X; Abasi X; Shapaer G; Aizimu A; Zhang S; Wan Y; Kamaer X; Tuerxun T; Abula R; Zhang Q
J BUON; 2018; 23(2):428-432. PubMed ID: 29745088
[TBL] [Abstract][Full Text] [Related]
36. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
[TBL] [Abstract][Full Text] [Related]
37. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma.
Li Z; Yin H; Ren M; Shen Y
Med Sci Monit; 2020 Sep; 26():e925051. PubMed ID: 32908118
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
Paek J; Lee M; Nam EJ; Kim SW; Kim YT
Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).
Farolfi A; Petrone M; Scarpi E; Gallà V; Greco F; Casanova C; Longo L; Cormio G; Orditura M; Bologna A; Zavallone L; Ventriglia J; Franzese E; Loizzi V; Giardina D; Pigozzi E; Cioffi R; Pignata S; Giorda G; De Giorgi U
Target Oncol; 2018 Aug; 13(4):469-479. PubMed ID: 29948780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
